Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A
Journal
Molecular Cancer Therapeutics
Journal Volume
10
Journal Issue
5
Pages
892-901
Date Issued
2011
Author(s)
Abstract
Previously, we have shown that bortezomib overcame TRAIL resistance in hepatocellular carcinoma (HCC) cells via the inhibition of Akt. Here, we report that bortezomib sensitizes these TRAIL-resistant cells, including Huh-7, Hep3B, and Sk-Hep1, to CS-1008, a humanized agonistic antihuman death receptor 5 antibody. Cancerous inhibitor of protein phosphatase 2A (CIP2A) mediated the sensitizing effect of bortezomib to CS-1008 through inhibiting protein phosphatase 2A (PP2A) activity. Combination treatment of bortezomib and CS-1008 downregulated CIP2A in a concentration- and time-dependent manner, and increased PP2A activity in HCC cells. Importantly, ectopic expression of CIP2A decreased Akt-related PP2A activity, indicating that CIP2A negatively regulates Akt-related PP2A activity in HCC cells. Moreover, silencing CIP2A by short interfering RNA enhanced CS-1008-induced apoptosis in HCC cells and ectopic expression of CIP2A in HCC cells abolished CS-1008-induced apoptosis, indicating that CIP2A plays an important role in the sensitizing effect of bortezomib to CS-1008. Finally, our in vivo data showed that CS-1008 and bortezomib combination treatment decreased tumor growth significantly. In conclusion, bortezomib sensitized HCC cells to CS-1008 through the inhibition of CIP2A. ?2011 AACR.
SDGs
Other Subjects
bortezomib; cancerous inhibitor of protein phosphatase 2a; phosphoprotein phosphatase 2A; protein kinase B; small interfering RNA; tigatuzumab; unclassified drug; animal experiment; animal model; apoptosis; article; cancer cell culture; cancer combination chemotherapy; controlled study; down regulation; drug mechanism; drug potentiation; drug sensitivity; human; human cell; liver cell carcinoma; male; mouse; nonhuman; priority journal; protein expression
Publisher
American Association for Cancer Research Inc.
Type
journal article